Daily Archives: December 16, 2024
RCT: Liberal vs Restrictive Transfusion Yields No Neurologic Outcome Benefit in Aneurysmal Subarachnoid Hemorrhage
16 Dec, 2024 | 11:26h | UTCBackground: Aneurysmal subarachnoid hemorrhage (SAH) is a critical neurologic condition associated with high morbidity and mortality. Anemia is common in this setting and may worsen cerebral oxygenation and outcomes. However, the impact of a liberal transfusion threshold compared with a restrictive approach on long-term neurologic outcomes has been uncertain.
Objective: To determine whether a liberal red blood cell transfusion strategy (transfusion at hemoglobin ≤10 g/dL) improves 12-month neurologic outcomes compared with a restrictive strategy (transfusion at hemoglobin ≤8 g/dL) in patients with aneurysmal SAH and anemia.
Methods: This was a multicenter, pragmatic, open-label, randomized controlled trial conducted at 23 specialized neurocritical care centers. Critically ill adults with a first-ever aneurysmal SAH and hemoglobin ≤10 g/dL within 10 days of admission were randomized to a liberal or restrictive transfusion strategy. The primary outcome was unfavorable neurologic outcome at 12 months, defined as a modified Rankin scale score ≥4. Secondary outcomes included the Functional Independence Measure (FIM), quality of life assessments, and imaging-based outcomes such as vasospasm and cerebral infarction. Outcome assessors were blinded to group allocation.
Results: Among 742 randomized patients, 725 were analyzed for the primary outcome. At 12 months, unfavorable neurologic outcome occurred in 33.5% of patients in the liberal group and 37.7% in the restrictive group (risk ratio 0.88; 95% CI, 0.72–1.09; p=0.22). There were no clinically meaningful differences in secondary outcomes. Mortality at 12 months was similar (approximately 27% in both arms). Radiographic vasospasm was more frequently detected in the restrictive group, though this did not translate into improved functional outcomes in the liberal arm. Adverse events and transfusion reactions were comparable between groups.
Conclusions: In patients with aneurysmal SAH and anemia, a liberal transfusion strategy did not lead to a significantly lower risk of unfavorable neurologic outcome at 12 months compared with a restrictive approach.
Implications for Practice: These findings suggest that routinely maintaining higher hemoglobin levels does not confer substantial long-term functional benefit. Clinicians may consider a more restrictive threshold (≤8 g/dL) to minimize unnecessary transfusions without compromising outcomes. Some skepticism toward adopting a more liberal transfusion policy is warranted given the lack of demonstrable benefit.
Study Strengths and Limitations: Strengths include the randomized, multicenter design, blinded outcome assessment, and a 12-month follow-up. Limitations include potential unmeasured subtle benefits, the inability to blind clinical teams, and the challenge of capturing all aspects of functional recovery with current measurement tools. Further research may clarify if more tailored transfusion strategies can yield modest but meaningful improvements.
Future Research: Future studies should evaluate intermediate hemoglobin thresholds, develop more sensitive measures of functional and cognitive recovery, and consider individualized transfusion strategies based on specific patient factors and biomarkers of cerebral ischemia.
Review: Enhancing Interpretability and Accuracy of AI Models in Healthcare
16 Dec, 2024 | 11:06h | UTCIntroduction: Artificial intelligence (AI) has shown remarkable potential in healthcare for improving diagnostics, predictive modeling, and treatment planning. However, the “black-box” nature of many high-performing AI models limits their trustworthiness and clinical utility. Challenges such as limited generalizability, variable performance across populations, and difficulty in explaining model decisions remain critical barriers to widespread adoption. This review synthesizes current evidence on AI models in healthcare, focusing on the interplay between model accuracy and interpretability. By highlighting these issues, we aim to guide healthcare professionals and researchers toward strategies that balance performance with transparency and reliability.
Key Recommendations:
- Adopt Interpretable Models: Incorporate interpretable frameworks (e.g., LIME, SHAP, Grad-CAM) that allow clinicians to understand model outputs. Such techniques facilitate better acceptance of AI-driven diagnostics, reducing the risk of misinterpretations and erroneous clinical decisions.
- Balance Accuracy and Transparency: Consider hybrid models that achieve high accuracy while maintaining a degree of explainability. Techniques that blend deep learning with simpler statistical or machine learning approaches can offer clinical insights into AI-derived predictions without substantially sacrificing performance.
- Integrate Uncertainty Quantification: Employ methods that estimate uncertainty in AI predictions, providing clinicians with confidence intervals or probability distributions. This approach helps manage expectations, enabling safer decision-making in critical clinical scenarios.
- Use Multimodal Data and Diverse Populations: Encourage the integration of multiple data sources—imaging, clinical notes, genomics—to improve model generalizability. Validate models on diverse patient cohorts to ensure robust performance across various healthcare environments and patient demographics.
- Collaborative, User-Centered Development: Engage healthcare professionals in the model development process to ensure clinical relevance and usability. User-centered design can guide AI solutions that seamlessly fit into existing workflows and foster greater trust among end-users.
Conclusion: The path to fully leveraging AI in healthcare involves overcoming interpretability challenges while maintaining accuracy. Implementing interpretable, uncertainty-aware models validated on diverse datasets will enhance trust, foster responsible adoption, and ultimately improve patient outcomes. By focusing on both technological innovation and user-centered development, we can drive AI models toward safer, more transparent, and clinically beneficial applications.